Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELA026 in secondary hemophagocytic lymphohistiocytosis
NL-OMON55948Phase 1Withdrawn
- Sponsor
- Electra Therapeutics
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ELA026 in haemophagocytic lymphohistiocytosis (HLH), sponsored by Electra Therapeutics. Primary endpoints: Safety and Recommended Phase 3 dose and schedule. Planned start Apr 2022; status: withdrawn.
02
Drugs
ELA026
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NL-OMON55948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55948.